DLL3 and large cell neuroendocrine carcinoma: However, Ogawa et al. [54] found that only 26 of 70 LCNEC patients had positive DLL3 expression, and found that the five-year OS after adjuvant therapy for patients with DLL3-negative tumors was 90.0%, compared with 26.9% for those without adjuvant therapy (p < 0.01).